louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00740701: Effects of Transcranial Magnetic Stimulation to the Cerebellum on Cognition
Official title: fMRI and TMS Analysis of Cerebellar Cognitive Function
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cognitive Performance
Keywords: TMS
fMRI
verbal working memory
classical conditioning
eyeblink
classical eyeblink conditioning
Healthy subjects
Memory
Lead sponsor: Johns Hopkins University
Sponsor class: OTHER
Collaborators: name: National Institute of Mental Health (NIMH)
name: National Institute on Aging (NIA)
First posted: 2008-08-25
Enrollment: 17
Sex: ALL
Minimum age (years): 19
Maximum age (years): 30
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: Functional neuroimaging studies have shown that the cerebellum is active during cognitive performance. The investigators hypothesize that stimulation of the cerebellum with transcranial magnetic stimulation will produce brief changes in performance of the task, suggesting that cerebellar activation is necessary for normal cognitive function.


Eligibility criteria: Inclusion Criteria:

* 19-30 years of age
* Informed consent

Exclusion Criteria:

* History of seizure or a family history of epilepsy
* History of stroke
* Presence of metal anywhere in the head except the mouth
* Presence of cardiac pacemakers
* Presence of cochlear implants
* Presence of implanted medication pump
* History of heart disease
* Presence of intracardiac lines
* Increased intracranial pressure, such as after infarctions or trauma
* Children, or outside of age range
* Pregnancy
* Currently taking tricyclic anti-depressants or neuroleptic medication
* History of head trauma
* History of respiratory disease

Primary outcomes:
measure: Behavioral performance (accuracy, or rate of conditioned responses)
timeFrame: during computerized task performance (2 hours)
Secondary outcomes:
measure: Reaction time
timeFrame: during performance of computerized task (2 hours)
Other outcomes:
Locations:
city: Baltimore
country: United States
facility: Kennedy Krieger Institute
state: Maryland
Study officials:
affiliation: Johns Hopkins University
name: John E Desmond, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06185101: Support, Training, and Education for Pain Self-Management Using Podcasts: A Pilot Trial
Official title: A Feasibility Study of a Chronic Pain Self-management Intervention for Older Adults Incorporating Podcasts and Patient Priorities
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Chronic Pain
Lead sponsor: University of Michigan
Sponsor class: OTHER
Collaborators: name: Western Wayne Family Health Centers
name: National Institute on Aging (NIA)
name: Weill Medical College of Cornell University
First posted: 2023-12-29
Enrollment: 40
Sex: ALL
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This randomized Stage 1 pilot trial tests the feasibility of a community health worker (CHW) delivered chronic pain self-management intervention for older adults ("STEP-UP"; Support, Training, and Education for Pain Self-Management - Using Podcasts) in a primary care setting. A total of 40 participants aged 50+ with high-impact chronic pain will be randomized to intervention or control groups. The STEP-UP intervention will feature an educational podcast series teaching core pain self-management skills. Podcasts will be supplemented by sessions with a Community Health Worker taking place at designated times over a 7-week period. The Community Health Worker will guide participants in a modified Patient Priorities of Care approach to help them identify their values and priorities and develop goals that reflect these.


Eligibility criteria: Inclusion Criteria:

* Age \> 50 years
* Have a mobile or landline phone
* Report high-impact chronic musculoskeletal pain (defined as pain in muscles or joints for \> 3 months "most days" or "every day" on a scale of never, some days, most days, or every day) AND their pain limited life or work activities over the past 3 months "most days" or "every day"
* Have not participated in another chronic pain self-management intervention in the last 5 years.
* Able to converse comfortably in English

Exclusion Criteria:

* Serious acute illness or hospitalization in the last month;
* Planned major surgery in the next three months that would interfere with program participation (e.g., knee or hip replacement)
* Severe cognitive impairment or other severe physical or psychiatric disorder judged by the study team to pose a significant barrier to participation

Primary outcomes:
measure: Change in Pain Interference 6-item subscale from PROMIS-43 Adult Profile
timeFrame: Baseline, 8 weeks from baseline
Secondary outcomes:
measure: Global Impression of Change in Pain
timeFrame: 8 weeks from baseline
measure: Global Impression of Change in Functioning
timeFrame: 8 weeks from baseline
measure: Engagement as measured by number of sessions completed
timeFrame: 8 weeks from baseline
measure: Participant Satisfaction
timeFrame: 8 weeks from baseline
Other outcomes:
Locations:
city: Ann Arbor
country: United States
facility: University of Michigan
state: Michigan
Study officials:
References:
Clinical trial NCT05587101: Neurogenic Lower Urinary Tract Symptoms in Patients With Multiple Sclerosis
Official title: Optimal Diagnostic Algorithm for Neurogenic Lower Urinary Tract Symptoms in Patients With MS
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Multiple Sclerosis
Neurogenic Bladder
Lead sponsor: Koç University
Sponsor class: OTHER
First posted: 2022-10-19
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patient with Multiple Sclerosis diagnosis less than 5 years

Brief summary: There is no consensus in the literature upon the neurourological diagnostic algorithm of the patients with multiple sclerosis (MS). The primary aim of the study is phenotyping the patients with MS. These phenotypes might guide Neurology and Urology specialists during diagnosis and treatment. Secondary aim of this study is to define the presence and severity of urological symptoms' and disorders', involving the patients with diagnosis of MS less than 5 years into a urological follow-up and treatment process. Our study might include 4 visits (the first visit, 3rd month, 6th month and 12th month visit). Questionnaires, uroflowmetry and bladder diary might be repeated on each visit. Filling cystometry and pressure-flow study will be performed only on the first visit. All patients will receive 6 different questionnaires which aim to define the severity and presence of lower urinary tract symptoms. Bladder diary is an online application which will represent at least 3 days of frequency, urgency, incontinence episodes and the amount of fluid intake, and urination. The phenotypes would be defined after performing the first visit diagnostic tools (all of the tools are necessary during the diagnostic algorithm of neurogenic lower urinary tract symptoms). The phenotypes will be defined as: a. no symptoms with normal urodynamics, b. Lower urinary tract symptoms with normal urodynamics, c. no symptoms with abnormal urodynamics, d.lower urinary tract symptoms with abnormal urodynamics. During a follow-up period of 1 year, changes in the bladder diaries and scores in questionnaires of these groups will be compared on each visit.


Eligibility criteria: Inclusion Criteria:

The patients who are followed up by Department of Neurology with MS diagnosis less than 5 years

Exclusion Criteria:

1. Patients who are not eligible for completing questionnaires, bladder diaries.
2. Patients who have anatomical disorders preventing lithotomy position during urodynamic study.
3. Patients in relapsing period of MS
4. Patients who have symptoms of urinary tract infection

Primary outcomes:
measure: Changes in Questionnaire Scores
timeFrame: every 3 months
measure: Changes in Urodynamics
timeFrame: every 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Koç University
Study officials:
affiliation: Koç University
name: Ersin Köseoğlu
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00406601: BAY-43-9006 in Advanced, Metastatic Soft Tissue Sarcomas
Official title: Phase II Prospective Study With BAY-43-9006 in Advanced, Metastatic Soft Tissue Sarcomas, After Anthracycline-based Therapy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Sarcoma, Soft Tissue
Lead sponsor: Istituto Clinico Humanitas
Sponsor class: OTHER
First posted: 2006-12-04
Enrollment: 69
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The aim of this study (\*) is to evaluate the progression free survival rate at 6 months, response rate, overall disease control rate, overall survival of BAY-43-9006 in soft tissue sarcoma patients.

(\*) as per Protocol Amendment No. 1 of 16 April 2007 approved by local IEC on 24 July 2007


Eligibility criteria: Inclusion Criteria:

* Histologically documented, progressive, advanced or metastatic sarcoma after adjuvant and/or first line anthracycline-based regimen; age \>=18 yrs; ECOG PS =2; at least 1 measurable target lesion; life expectancy \>=12 wks; adequate medullary liver and renal function; written informed consent.

Exclusion Criteria:

* metastatic brain disease; pregnant or breast-feeding patients; serious infections.

Primary outcomes:
measure: Progression free survival rate
timeFrame: at 6 months after enrollment
Secondary outcomes:
measure: Overall response rate, overall disease control rate, overall survival
timeFrame: Tumor assessment, follow-up
Other outcomes:
Locations:
city: Rozzano
country: Italy
facility: Istituto Clinico Humanitas
state: Milan
Study officials:
affiliation: Istituto Clinico Humanitas
name: Armando Santoro, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Antman KH. Adjuvant therapy of sarcomas of soft tissue. Semin Oncol. 1997 Oct;24(5):556-60.
citation: Santoro A, Tursz T, Mouridsen H, Verweij J, Steward W, Somers R, Buesa J, Casali P, Spooner D, Rankin E, et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol. 1995 Jul;13(7):1537-45. doi: 10.1200/JCO.1995.13.7.1537.
Clinical trial NCT06805201: The Effects of Gyngerlean Supplementation on Energy Expenditure
Official title: The Acute Metabolic Impacts of Kaempferia Parviflora Extract in Healthy Men: a Randomized Double Blind Proof of Concept Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: No Disease or Condition is Being Studied
Metabolism
Lead sponsor: Nova Southeastern University
Sponsor class: OTHER
First posted: 2025-02-03
Enrollment: 10
Sex: MALE
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: The goal of this randomized controlled study is to asses the effects of a ginger containing supplement on energy expenditure and substrate utilization in healthy men. The main questions it aims to answer are"

* The effects of Kaempferia parviflora extract on energy expenditure
* The effects of Kaempferia parviflora extract on substrate utilization


Eligibility criteria: Inclusion Criteria:

* Active adults. Active is defined as exercising 3 or more times a week for 30 minutes.

Exclusion Criteria:

* Participants must not be diabetics, have Celiac disease, or individuals with pre-existing heart or kidney disease.

Primary outcomes:
measure: Resting Metabolic rate
timeFrame: 180 minutes
Secondary outcomes:
measure: Respiratory quotient
timeFrame: 180 minutes
Other outcomes:
Locations:
city: Davie
country: United States
facility: Nova Southeastern University
state: Florida
Study officials:
affiliation: ljiannine@nova.edu
name: Lia Jiannine
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06950801: Comparing the Effects of Indoor vs. Outdoor Horticultural Therapy on College Students
Official title: Comparing the Effects of Indoor vs. Outdoor Horticultural Therapy on College Students
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Healthy
Lead sponsor: Central University of Finance and Economics, China
Sponsor class: OTHER
First posted: 2025-04-30
Enrollment: 120
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: This study used a randomised controlled trial to investigate the effects of different forms of horticultural group interventions on college students' depression, anxiety and subjective well-being, and the internal mechanisms of the effects.

Participants are required to complete the following tasks:

Attend one indoor/outdoor group gardening activity per week, lasting 2 hours each session, for a total of 8 weeks.

Complete psychological scale assessments at five time points: before the activity begins, at 4 weeks after the start, upon completion of the activity, and at 1 week and 2 weeks after completion.


Eligibility criteria: Inclusion Criteria:

- University students

Exclusion Criteria:

* Diagnosed with a mental disorder

Primary outcomes:
measure: Depression
timeFrame: From enrollment to 2 weeks after the completion of the 8-week treatment Edit Copy Outcome
measure: Anxiety
timeFrame: From enrollment to 2 weeks after the completion of the 8-week treatment
measure: Positive And Negative Affective
timeFrame: From enrollment to 2 weeks after the completion of the 8-week treatment
measure: Life satisfaction
timeFrame: From enrollment to 2 weeks after the completion of the 8-week treatment
Secondary outcomes:
measure: Resilience
timeFrame: From enrollment to 2 weeks after the completion of the 8-week treatment
measure: Loneliness
timeFrame: From enrollment to 2 weeks after the completion of the 8-week treatment
measure: Sense of control
timeFrame: From enrollment to 2 weeks after the completion of the 8-week treatment
measure: Avoidance
timeFrame: From enrollment to 2 weeks after the completion of the 8-week treatment
measure: Self-concept
timeFrame: From enrollment to 2 weeks after the completion of the 8-week treatment
measure: meaning in life
timeFrame: From enrollment to 2 weeks after the completion of the 8-week treatment
measure: Grit
timeFrame: From enrollment to 2 weeks after the completion of the 8-week treatment
measure: nature connection
timeFrame: From enrollment to 2 weeks after the completion of the 8-week treatment
Other outcomes:
Locations:
city: Beijing
country: China
facility: Central University of Finance and Economics, Beijing, Beijing 100875
state: Beijing
Study officials:
References:
Clinical trial NCT01429701: Effectiveness of Polymyxin B Sulphate + Prednisolone + Benzocaine + Clioquinol in Acute and Sub-acute Dermatitis Eczematous
Official title: Unicentric Comparing Effectiveness of Polymyxin B Sulphate + Prednisolone + Benzocaine + Clioquinol to Betamethasone + Gentamicin + Tolnaftate + Clioquinol in Acute and Sub-acute Dermatitis Eczematous
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Eczema
Keywords: Dermatitis
Dermatitis, Atopic
Lead sponsor: EMS
Sponsor class: INDUSTRY
First posted: 2011-09-07
Enrollment: 76
Sex: ALL
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Dermatitis eczematous is a recurrent pruritic skin disorder which has a significant morbidity and impaired quality of life due specially pruritus and physical visible skin lesions. The purpose of this trial is evaluate the effectiveness of two different topic associations of drugs.

Detailed description: Study design:

* Experiment duration: 22 days
* 2 visits (days 0,7,15 and 22)
* Reducing eczema area and severity index evaluation
* Adverse events evaluation
* Double blinded, non-inferiority, prospective parallel-group, intend to treat trial.

Eligibility criteria: Inclusion Criteria:

1. Patients must be able to understand the study procedures agree to participate and give written consent.
2. Patients with acute or subacute dermatitis with a minimum of 3 symptoms.

Exclusion Criteria:

1. Pregnancy or risk of pregnancy.
2. Lactation
3. Use of anti-inflammatory or immunosuppressive drugs (last 30 days prior to the study).
4. Sunlight over exposure in the last 15 days.
5. Any pathology or past medical condition that can interfere with this protocol.

Primary outcomes:
measure: Reduction / improvement of signs and symptoms
timeFrame: DAY 22
Secondary outcomes:
measure: Adverse Events Evaluation
timeFrame: DAY 22
Other outcomes:
Locations:
Study officials:
affiliation: Medicin Instituto da Pele
name: Flávia Addór, MD.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02776501: 18572 - Sun Protection Factor Assay
Official title: Sun Protection Factor (SPF) Assay: UVA Protection Factor Assay on Minimal Persistent Pigment-Darkening Dose.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Sunscreening Agent
Lead sponsor: Bayer
Sponsor class: INDUSTRY
First posted: 2016-05-18
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To evaluate the Sun Protection Factor efficacy on human skin.


Eligibility criteria: Inclusion Criteria:

* Fitzpatrick Skin Type l, ll and/or lll for UVB testing. Fitzpatrick Skin Type ll, lll and/or lV for UVA testing.
* Male and female
* Aged between 18-70 years old.
* Good health as determined from the HRL SHF
* Signed and dated Informed Consent Form
* Signed and dated HIPAA Form
* An unambiguous MED or MPPD (Minimal Persistent Pigment Darkening Dose)

Exclusion Criteria:

* Subjects on test at any other research laboratory or clinic.
* Known allergy or sensitivity to sunscreens, cosmetics and toiletries, topical drugs and/or ultraviolet light.
* Pre-existing dermatologic conditions which have been diagnoses by a medical professional (e.g. psoriasis, eczema, etc.) which would interfere with this study.
* Pre-existing other medical conditions (e.g. adult asthma. diabetes).
* Treatment with antihistamines or corticosteroids within one week prior to initiation of the test.
* Treatment with antibiotics within two weeks prior to initiation of the test.
* Chronic medication which could affect the results of the study.
* Known pregnant or nursing women.

Primary outcomes:
measure: Minimal Erythema Dose (MED)
timeFrame: Up to 15 minutes
measure: Minimal Persistent Pigment Darkening Dose (MPPD)
timeFrame: Up to 15 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Union
country: United States
state: New Jersey
Study officials:
affiliation: Bayer
name: Bayer Study Director
role: STUDY_DIRECTOR
References:
Clinical trial NCT06151301: Evaluation of the Role of Poisoning Severity Score, Serum Procalcitonin and C-reactive Protein in Acute Hydrocarbon Intoxicated Cases Admitted to the Poison Control Center Ain Shams University Hospitals
Official title: Evaluation of the Role of Poisoning Severity Score, Serum Procalcitonin and C-reactive Protein in Acute Hydrocarbon Intoxicated Cases Admitted to the Poison Control Center Ain Shams University Hospitals
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Acute Hydrocarbon Toxicity
Lead sponsor: Sohag University
Sponsor class: OTHER
First posted: 2023-11-30
Enrollment: 60
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients of both sexes admitted to the Poison control center, Ain Shams university hospitals with acute hydrocarbon toxicity during the duration from December 2023 till December 2024 with a maximum number of 60 cases within 24 hours of intoxication

Brief summary: Hydrocarbons are a primary energy source in modern society. They are present in many common household and occupational products, including motor fuels, paint thinners, cleaning agents, lotions, and industrial solvents. Unfortunately, these products are also used as agents of abuse and typically inhaled .

They are derived mainly from petroleum (kerosene, gas, naphtha) or wood (turpentine, pine oil). They can be found in liquid, gas, or solid form depending on their properties. All hydrocarbons can be toxic, but aromatic (ring-shaped) and halogenated hydrocarbons typically have more severe toxicity .

Toxicity occurs in various ways including through inhalation, ingestion, aspiration, and dermal exposure. Frequently, these exposures occur during attempted recreational use of the substances and sometimes for self-injurious behavior


Eligibility criteria: Inclusion Criteria:

Patients of both sexes admitted to the Poison control center, Ain Shams university hospitals with acute hydrocarbon toxicity during the duration from December 2023 till December 2024 with a maximum number of 60 cases within 24 hours of intoxication.

Exclusion Criteria:

Patients with these criteria will be excluded:

* Cases \> 24 hours of intoxication.
* Cases with occupational exposure to hydrocarbons.
* Pregnant females.
* Any cases received any treatment before arrival to the PCC.
* Cases suffering from cardiac, respiratory, renal, hepatic or haematological disorders.
* Cases presenting with fever.
* Cases with other causes that can increase levels of CRP \& pro-calcitonin as bacterial infection, recent major trauma, major burn ,septic shock and medullary thyroid cancer.

Primary outcomes:
measure: Serum procalcitonin level
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Ain Shams university Hospital
Study officials:
References: